A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma

15457RP2-202-NCT06581406OpenA Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal MelanomaRP2-202NCT06581406IndustrialAdultTreatmentII/IIIMelanoma, SkinRapisuwon, SutheeGeorgetown University Medical Center : Jamie Manganti; Lombardi Comprehensive Cancer Center : Jamie MangantiMelanomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16801Jamie MangantiJamie Mangantijm3821@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>